Castle Biosciences (CSTL) COO Kristen Oelschlager Sells Shares

What Happened
Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences (CSTL), reported open-market sales totaling 24,602 shares across Aug. 24–25, 2026, for aggregate proceeds of approximately $837,864. The individual sales reported were: 12,218 shares at a weighted-average price of $33.69 (≈ $411,588), 7,161 shares at $34.26 (≈ $245,357), and 5,223 shares at $34.64 (≈ $180,919). These were dispositions (sales), which are routine insider transactions and do not by themselves indicate management’s view of the company.

Key Details

• Transaction dates and amounts:
  • 2026-08-24: 12,218 shares sold, weighted-average $33.69, proceeds ≈ $411,588 (multiple trades at $33.500–$33.885; weighted avg reported) [Footnote F1].
  • 2026-08-25: 7,161 shares sold, weighted-average $34.26, proceeds ≈ $245,357 (multiple trades at $33.470–$34.460; weighted avg reported) [Footnote F3].
  • 2026-08-25: 5,223 shares sold, weighted-average $34.64, proceeds ≈ $180,919 (multiple trades at $34.495–$34.750; weighted avg reported) [Footnote F4].
• Aggregate shares sold: 24,602; aggregate proceeds: ≈ $837,864.
• Holdings after the transaction: Not disclosed in the provided excerpt of the filing.
• Notable footnote: Some shares are/were held by the Fritz Shorter Trust of which the reporting person and her spouse are trustees and beneficiaries (Footnote F2). Multiple trades were aggregated and reported as weighted-average prices; the filer offered to provide trade-level details on request to the SEC or issuer.
• Timeliness: The provided excerpt does not indicate a late-filing flag.

Context

• These transactions are straight sales (transaction code S) executed in the open market. Sales by officers can be for many reasons (diversification, tax planning, trust needs, etc.), and routine sales do not necessarily signal a change in company outlook.
• If you track insider activity, purchases tend to be more informative about positive insider sentiment; sales are common and should be viewed alongside other signals (e.g., recurring sales, changes in ownership percentage, and company fundamentals).